
Modest weight loss (>3%) among metformin-treated patients with type 2 diabetes mellitus was associated with decreased costs, lower resource utilization, and lower rates of treatment discontinuation.

Modest weight loss (>3%) among metformin-treated patients with type 2 diabetes mellitus was associated with decreased costs, lower resource utilization, and lower rates of treatment discontinuation.

Initiation of fluticasone propionate–salmeterol after a COPD-related hospitalization or ED visit decreased the risk of a recurrent event and reduced COPD-related medical costs.